medigraphic.com

2017, Number 1

<< Back

Rev Clin Esc Med 2017; 7 (1)

Aspectos básicos del bordaje Integral de las supervivientes de cáncer de mama

Landaverde D

Language: Spanish
References: 38
Page: 11-18
PDF size: 302.29 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Global Health Estimates, WHO 2013, http://www.who.int/cancer/detection/breastc ancer/en/index1.html

  2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet].Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 10/08/2016.

  3. Coleman MP, et al. Cancer survival in five continents: a worldwidepopulation-based study (CONCORD). Lancet 2008; 9: 730- 756

  4. Justo N. et al. A Review of Breast Cancer Care and Outcomes in Latin America. The Oncologist 2013;18:248–256

  5. Dirven L, Van de Poll Franse LV, Aaronson NK, Reijneveld JC. Controversies in defining cancer survivorship. Lancet Oncol 2015; 16(6):610-2.

  6. National Coalition for Cancer Survivorship (NCCS). NCCS Mission,2016. http://www.cancercontrol.cancer.gov/aboutus/ our-mission. Accessed June 18, 2016

  7. National Cancer Institute (NCI) Office of Cancer Survivorship. Definitions, 2016. http://www.cancer.gov/publications/dictionar ies/cancer-terms?cdrid=445089. Accessed June18, 2016

  8. Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006;24:5117-5124.

  9. Grunfeld E, Levine MN, Julian JA, et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol. 2006. 24:848-855.

  10. Grunfeld E, Mant D, Yudkin P, et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ. 1996;313:665-669

  11. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016; 34:611-35

  12. Salloum RG, Hornbrook MC, Fishman PA, et al. Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent. Cancer 2012; 118 (22):5644-51

  13. Keating NL, Landrum MB, Guadagnoli E, et al. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol 2007; 25:1074

  14. Wood ME, Vogel V, Ng A, et al. Second Malignant neoplasm: assessment and strategies for risk reduction. J Clin Oncolo 2012; 30:3734

  15. Curtis RE, Freedman DM, Ron E, et al. New Malignancies among Cancer Survivor: Seer Cancer Registries, 1973-2000. NIH Publication No. 05-5302 181-186. Washington, DC: National Cancer Institute;2006.

  16. Bodai BI, Tuso P. Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations. Perm J. 2015 19(2):48- 79

  17. Ligibel JA, Alfano CM, Corneya KS, et al. American Society of Clinical Oncology position statement on obesity and cáncer. J Clin Oncol 2014 32:3568-3574

  18. Playdon MC, Bracken MD, Sanft TB. et al. Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst. 2015; 107:djv275

  19. Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:379- 386

  20. Irwin ML, McTiernan A, Manson JE, et al. Physical activity and survival in postmenopausal women with breast cáncer: Results from the women’ health initiative. Cancer Prev Res (Phila). 2011;4:522-529

  21. Chlebowski RT, Blackburn GL, Thompson CA, et al. Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst. 2006;98:1767- 1776

  22. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a dietary very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cáncer: the Women’s Healthy Eating and Living (WHEL) randomized trial. JAMA 2007;298:289-298

  23. Berube S, Lemieux J, Moore L, Maunsell E, Brisson J. Smoking at time of diagnosis and breast cancer-specific survival: New findings and systematic review with metaanalysis. Breast Cancer Res. 2014;16:R42

  24. Kwan ML, Chen WY, Flatt SW, et al. Postdianosis alcohol consumption and breast cancer prognosis in the after breast cancer pooling project. Cancer Epidemiol Biomarkers Prev. 2013;22:32-41

  25. Flatt SW, Thomson CA, Gold EB, et al. Low to moderate alcohol intake is not associated with increased mortality after breast cancer. Cancer Epidemiolol Biomarkers Prev 2010;19:681-688

  26. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health in Carcer Care. J Natl Compr Canc Netw 2013 11:S1-S50; quiz S51 (suppl 3)

  27. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteroporos Int 2014;25:2359-2381

  28. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9:77-85

  29. Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial:adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012;118: 1192- 1201.

  30. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZOFAST study): final 60-month results. Ann Oncol. 2013;24:398-405.

  31. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36- month results of the ZO-FAST Study. Ann Oncol. 2010;21: 2188-2194.

  32. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non metastatic breast cancer. J Clin Oncol. 2008;26:4875-4882.

  33. Coleman R, Powles T, Paterson A, et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353-1361.

  34. Ganz PA, Hahn EE. Implementing a Survivorship Care Plan for Patients with Breast Cancer. J Clin Oncol 2008;26(5):759- 767

  35. Smith E, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapyinduced painful peripheral neuropathy: A randomized clinical trial. JAMA 2013;309:1359-1367

  36. Kaplan M, Mahon S, Cope D, et al. Putting evidence into practice: Evidence-based interventions for hot flashes resulting from cancer therapies. Clin J Oncol Nurs 2011;15:149-157

  37. Burstein HJ, Prestrud AA, Seidfeld J, et al. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J clin Oncol 2010 28:3784-3796

  38. Harrington CB, Hansen JA, Moskowitz M, et al. It’s not over when it’s over: long-term symptoms in cancer survivor-a systematic review. Int J Psychiatry Med 2010;40:163




2020     |     www.medigraphic.com